1
|
Cao J, Zhou A, Zhou Z, Liu H, Jia S. The role of GPLD1 in chronic diseases. J Cell Physiol 2023. [PMID: 37393554 DOI: 10.1002/jcp.31041] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2022] [Revised: 04/07/2023] [Accepted: 04/17/2023] [Indexed: 07/04/2023]
Abstract
Glycosylphosphatidylinositol-specific phospholipase D (GPLD1) is a specific enzyme for glycosylphosphatidylinositol (GPI) anchors, thereby exerting its biological functions by cleaving membrane-associated GPI molecules. GPLD1 is abundant in serum, with a concentration of approximately 5-10 µg/mL. Previous studies have demonstrated that GPLD1 plays a crucial role in the pathogenesis of numerous chronic diseases including disorders of lipid and glucose metabolism, cancer, and neurological disorders. In the present study, we reviewed the structure, functions, and localization of GPLD1 in chronic diseases, as well as exercise-mediated regulation of GPLD1, thus providing a theoretical support to develop GPLD1 as a new therapeutic target for chronic diseases.
Collapse
Affiliation(s)
- Jing Cao
- Graduate School of Wuhan Sports University, Wuhan, China
| | - Anni Zhou
- Graduate School of Wuhan Sports University, Wuhan, China
| | - Zhuoyang Zhou
- Graduate School of Wuhan Sports University, Wuhan, China
| | - Hui Liu
- School of Physical Education, Jinan University, Jinan, China
| | - Shaohui Jia
- Hubei Key Laboratory of Sport Training and Monitoring, Tianjiu Research and Development Center for Exercise Nutrition and Foods, College of Health Science, Wuhan Sports University, Wuhan, China
| |
Collapse
|
2
|
Bistrović A, Grbčić P, Harej A, Sedić M, Kraljević-Pavelić S, Koštrun S, Plavec J, Makuc D, Raić-Malić S. Small molecule purine and pseudopurine derivatives: synthesis, cytostatic evaluations and investigation of growth inhibitory effect in non-small cell lung cancer A549. J Enzyme Inhib Med Chem 2018; 33:271-285. [PMID: 29271659 PMCID: PMC6009932 DOI: 10.1080/14756366.2017.1414807] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Novel halogenated purines and pseudopurines with diverse aryl-substituted 1,2,3-triazoles were prepared. While p-(trifluoromethyl)-substituted 1,2,3-triazole in N-9 alkylated purine and 3-deazapurine was critical for strong albeit unselective activity on pancreatic adenocarcinoma cells CFPAC-1,1-(p-fluorophenyl)-1,2,3-triazole derivative of 7-deazapurine showed selective cytostatic effect on metastatic colon cancer cells SW620. Importantly, 1-(p-chlorophenyl)-1,2,3-triazole-tagged benzimidazole displayed the most pronounced and highly selective inhibitory effect in nM range on non-small cell lung cancer A549. This compound revealed to target molecular processes at the extracellular side and inside the plasma membrane regulated by GPLD1 and growth factor receptors PDGFR and IGF-1R leading to the inhibition of cell proliferation and induction of apoptosis mediated by p38 MAP kinase and NF-κB, respectively. Further optimisation of this compound as to reduce its toxicity in normal cells may lead to the development of novel agent effective against lung cancer.
Collapse
Affiliation(s)
- Andrea Bistrović
- a Department of Organic Chemistry, Faculty of Chemical Engineering and Technology , University of Zagreb , Zagreb , Croatia
| | - Petra Grbčić
- b Department of Biotechnology, Center for High-Throughput Technologies , University of Rijeka , Rijeka , Croatia
| | - Anja Harej
- b Department of Biotechnology, Center for High-Throughput Technologies , University of Rijeka , Rijeka , Croatia
| | - Mirela Sedić
- b Department of Biotechnology, Center for High-Throughput Technologies , University of Rijeka , Rijeka , Croatia
| | - Sandra Kraljević-Pavelić
- b Department of Biotechnology, Center for High-Throughput Technologies , University of Rijeka , Rijeka , Croatia
| | - Sanja Koštrun
- c Chemistry Department , Fidelta Ltd. , Zagreb , Croatia
| | - Janez Plavec
- d Slovenian NMR Centre , National Institute of Chemistry , Ljubljana , Slovenia.,e En-FIST Centre of Excellence , Ljubljana , Slovenia.,f Faculty of Chemistry and Chemical Technology , University of Ljubljana , Ljubljana , Slovenia
| | - Damjan Makuc
- d Slovenian NMR Centre , National Institute of Chemistry , Ljubljana , Slovenia.,e En-FIST Centre of Excellence , Ljubljana , Slovenia
| | - Silvana Raić-Malić
- a Department of Organic Chemistry, Faculty of Chemical Engineering and Technology , University of Zagreb , Zagreb , Croatia
| |
Collapse
|
3
|
Azevedo R, Peixoto A, Gaiteiro C, Fernandes E, Neves M, Lima L, Santos LL, Ferreira JA. Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology? Oncotarget 2017; 8:91734-91764. [PMID: 29207682 PMCID: PMC5710962 DOI: 10.18632/oncotarget.19433] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2017] [Accepted: 06/19/2017] [Indexed: 12/19/2022] Open
Abstract
The high molecular heterogeneity of bladder tumours is responsible for significant variations in disease course, as well as elevated recurrence and progression rates, thereby hampering the introduction of more effective targeted therapeutics. The implementation of precision oncology settings supported by robust molecular models for individualization of patient management is warranted. This effort requires a comprehensive integration of large sets of panomics data that is yet to be fully achieved. Contributing to this goal, over 40 years of bladder cancer glycobiology have disclosed a plethora of cancer-specific glycans and glycoconjugates (glycoproteins, glycolipids, proteoglycans) accompanying disease progressions and dissemination. This review comprehensively addresses the main structural findings in the field and consequent biological and clinical implications. Given the cell surface and secreted nature of these molecules, we further discuss their potential for non-invasive detection and therapeutic development. Moreover, we highlight novel mass-spectrometry-based high-throughput analytical and bioinformatics tools to interrogate the glycome in the postgenomic era. Ultimately, we outline a roadmap to guide future developments in glycomics envisaging clinical implementation.
Collapse
Affiliation(s)
- Rita Azevedo
- Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Porto, Portugal
- Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal
| | - Andreia Peixoto
- Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Porto, Portugal
- Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal
- New Therapies Group, INEB-Institute for Biomedical Engineering, Porto, Portugal
- Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
| | - Cristiana Gaiteiro
- Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Porto, Portugal
| | - Elisabete Fernandes
- Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Porto, Portugal
- Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal
- Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
- Biomaterials for Multistage Drug and Cell Delivery, INEB-Institute for Biomedical Engineering, Porto, Portugal
| | - Manuel Neves
- Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Porto, Portugal
- Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal
| | - Luís Lima
- Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Porto, Portugal
- Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
- Glycobiology in Cancer, Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal
| | - Lúcio Lara Santos
- Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Porto, Portugal
- Department of Surgical Oncology, Portuguese Institute of Oncology, Porto, Portugal
| | - José Alexandre Ferreira
- Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Porto, Portugal
- Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal
- Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
- Glycobiology in Cancer, Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal
| |
Collapse
|
4
|
Three-finger snake neurotoxins and Ly6 proteins targeting nicotinic acetylcholine receptors: pharmacological tools and endogenous modulators. Trends Pharmacol Sci 2014; 36:109-23. [PMID: 25528970 DOI: 10.1016/j.tips.2014.11.003] [Citation(s) in RCA: 80] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2014] [Revised: 11/04/2014] [Accepted: 11/10/2014] [Indexed: 02/07/2023]
Abstract
Snake venom neurotoxins and lymphocyte antigen 6 (Ly6) proteins, most of the latter being membrane tethered by a glycosylphosphatidylinositol (GPI) anchor, have a variety of biological activities, but their three-finger (3F) folding combines them in one Ly6/neurotoxin family. Subsets of two groups, represented by α-neurotoxins and Lynx1, respectively, interact with nicotinic acetylcholine receptors (nAChR) and, hence, are of therapeutic interest for the treatment of neurodegenerative diseases, pain, and cancer. Information on the mechanisms of action and 3D structure of the binding sites, which is required for drug design, is available from the 3D structure of α-neurotoxin complexes with nAChR models. Here, I compare the structural and functional features of α-neurotoxins versus Lynx1 and its homologs to get a clearer picture of Lynx1-nAChR interactions that is necessary for fundamental science and practical applications.
Collapse
|
5
|
Phospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizations. Int J Mol Sci 2013; 14:5036-129. [PMID: 23455471 PMCID: PMC3634480 DOI: 10.3390/ijms14035036] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2012] [Revised: 01/24/2013] [Accepted: 01/25/2013] [Indexed: 02/08/2023] Open
Abstract
The present review aims to systematically and critically analyze the current knowledge on phospholipases and their role in physiological and pathological mineralization undertaken by mineralization competent cells. Cellular lipid metabolism plays an important role in biological mineralization. The physiological mechanisms of mineralization are likely to take place in tissues other than in bones and teeth under specific pathological conditions. For instance, vascular calcification in arteries of patients with renal failure, diabetes mellitus or atherosclerosis recapitulates the mechanisms of bone formation. Osteoporosis—a bone resorbing disease—and rheumatoid arthritis originating from the inflammation in the synovium are also affected by cellular lipid metabolism. The focus is on the lipid metabolism due to the effects of dietary lipids on bone health. These and other phenomena indicate that phospholipases may participate in bone remodelling as evidenced by their expression in smooth muscle cells, in bone forming osteoblasts, chondrocytes and in bone resorbing osteoclasts. Among various enzymes involved, phospholipases A1 or A2, phospholipase C, phospholipase D, autotaxin and sphingomyelinase are engaged in membrane lipid remodelling during early stages of mineralization and cell maturation in mineralization-competent cells. Numerous experimental evidences suggested that phospholipases exert their action at various stages of mineralization by affecting intracellular signaling and cell differentiation. The lipid metabolites—such as arachidonic acid, lysophospholipids, and sphingosine-1-phosphate are involved in cell signaling and inflammation reactions. Phospholipases are also important members of the cellular machinery engaged in matrix vesicle (MV) biogenesis and exocytosis. They may favour mineral formation inside MVs, may catalyse MV membrane breakdown necessary for the release of mineral deposits into extracellular matrix (ECM), or participate in hydrolysis of ECM. The biological functions of phospholipases are discussed from the perspective of animal and cellular knockout models, as well as disease implications, development of potent inhibitors and therapeutic interventions.
Collapse
|
6
|
Regulation of carcinoembryonic antigen release from colorectal cancer cells. Mol Biol Rep 2011; 39:3695-704. [PMID: 21725636 DOI: 10.1007/s11033-011-1144-0] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2011] [Accepted: 06/24/2011] [Indexed: 01/13/2023]
Abstract
Clinical and experimental evidence suggest that circulating carcinoembryonic antigen (CEA) released from tumor cells has an instrumental role in colorectal cancer-liver metastasis. However, the precise mechanism of the regulation of the CEA release from cancer cells is not known. We investigated if the rate of CEA and another GPI-anchored protein, alkaline phosphatase (AP) release is correlated with cellular glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD) expression. We also evaluated the effects of phosphatidic acid (PA), a compound known to inhibit GPI-PLD activity, on the CEA and AP release from colon cancer cells. The expression of CEA, GPI-PLD, and AP in five colon carcinoma cells (LS180, Caco2, SW742, SW1116, and HT29/219) was verified by immunoblot and real-time RT-PCR analysis. The amounts of CEA and AP released into cell culture media were determined using ELISA and a colorimetric assay, respectively. We examined the effects of PA (20-100 μM) on CEA and AP release from LS180 cells. All five cancer cell lines analyzed expressed GPI-PLD protein. While there was a positive relationship between AP release and the levels of GPI-PLD transcript expression, we found no direct correlation between CEA released from cancer cells and the GPI-PLD mRNA expression level. However, the rate of CEA release was positively associated with the level of CEA transcript expression. In comparison to controls, the release of GPI-anchored CEA and AP, but not CA19-9 was inhibited significantly by both crude and pure phosphatidic acid (by 56 and 54.5%, respectively). Using PA for inhibiting CEA release from cancer cells may have therapeutic application in preventing CRC-liver metastasis.
Collapse
|
7
|
Abstract
Complex carbohydrates, which are major components of the cell membrane, perform important functions in cell-cell and cell-extracellular matrix interactions, as well as in signal transduction. They comprise three kinds of biomolecules: glycoproteins, proteoglycans and glycosphingolipids. Recent studies have also shown that glycan changes in malignant cells take a variety of forms and mediate key pathophysiological events during the various stages of tumour progression. Glycosylation changes are universal hallmarks of malignant transformation and tumour progression in human cancer, which take place on the whole cells or some specific molecules. Accordingly, those changes make them prominent candidates for cancer biomarkers in the meantime. This review mainly focuses on the correlation between glycosylation and the metastasis potential of tumour cells from comprehensive aspects to further address the vital roles of glycans in oncogenesising. Moreover, utilizing these glycosylation changes to ward off tumour metastasis by means of anti-adhesion approach or devising anti-cancer vaccine is one of promising targets of future study.
Collapse
Affiliation(s)
- Min Li
- Department of General Surgery, Zhongshan Hospital, Shanghai Medical School, Fudan University, 180, Fenglin Road, Shanghai, 200032, China
| | | | | |
Collapse
|
8
|
Proteomic profiling of lipid rafts in a human breast cancer model of tumorigenic progression. Clin Exp Metastasis 2011; 28:529-40. [PMID: 21533873 DOI: 10.1007/s10585-011-9389-5] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2010] [Accepted: 04/10/2011] [Indexed: 12/27/2022]
Abstract
Tumor biomarkers assist in the early detection of cancer, act as therapeutic targets for intervention, and function as diagnostic indicators for the evaluation of therapeutic responses. To identify novel human breast cancer biomarkers, we have analyzed the protein content of lipid rafts isolated from a series of human mammary epithelial cell lines with increasing tumorigenic potential. Since lipid rafts function as platforms for protein interaction critical to several biological processes, we hypothesized that the abundance of proteins associated with proliferation, invasion and metastasis would be dysregulated in highly transformed cells. For this purpose, the MCF10A epithelial lineage, which include benign MCF10A cells, premalignant AT and TG3B cells, and malignant CA1a tumor cells, was utilized. Detergent-resistant membranes were isolated from each line and proteins were identified and relatively quantitated using iTRAQ™ reagents and tandem mass spectrometry. 57 proteins were identified, and 1667 peptide identifications, mapping to 49 proteins, contained sufficient information for semi-quantitative analysis. When comparing malignant to benign cells, we observed consistent alterations in groups of proteins, such as a 5.7-fold average decrease in G protein content (n = 5), 2.7-fold decrease in glycosylphosphatidylinositol-linked proteins (n = 7) and 3.3-fold increase in intermediate filaments (n = 9). Several of the identified proteins, including caveolin-1, filamin A, keratins 5, 6 and 17, and vimentin, are bona fide or candidate biomarkers in clinical studies, underscoring the usefulness of the MCF10A series as a model to better understand the biological mechanisms underlying cancer progression.
Collapse
|
9
|
Important roles of glycosylphosphatidylinositol (GPI)-specific phospholipase D and some GPI-anchored proteins in the pathogenesis of hepatocellular carcinoma. Clin Biochem 2008; 42:400-7. [PMID: 19135435 DOI: 10.1016/j.clinbiochem.2008.11.019] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2008] [Revised: 10/27/2008] [Accepted: 11/27/2008] [Indexed: 01/07/2023]
Abstract
OBJECTIVE To investigate the roles of glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD) in the pathogenesis of hepatocellular carcinoma (HCC). METHODS The expression of the GPI-PLD in HCC was determined. The GPI-PLD gene was stably transfected in HepG2 cells and the proliferation of these cells was detected; CD55, CD59 and apoptotic cells were also analyzed. RESULTS The serum GPI-PLD activities, the protein and mRNA levels of GPI-PLD in HCC patients were decreased by 40%, 60% and 56%, respectively. The killing rate of CDC against the positive clone cells was significantly increased, but the proliferative capacity was obviously decreased. The apoptotic rate in positive clones was increased. CONCLUSION The expression of GPI-PLD decreases in HCC patients. The over-expression of GPI-PLD in HepG2 cells increases their sensitivity to CDC killing, impairs proliferative capacity and promotes apoptosis.
Collapse
|
10
|
Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R, Anderson GL, Urban N. Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA. Clin Cancer Res 2008; 14:2647-55. [PMID: 18451228 DOI: 10.1158/1078-0432.ccr-07-1442] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
PURPOSE To measure circulating antigens, sandwich ELISA assays require two complementary affinity reagents. Mouse monoclonal antibodies (mAb) and polyclonal antibodies (pAb) are commonly used, but because their production is lengthy and costly, recombinant antibodies are emerging as an attractive alternative. EXPERIMENTAL DESIGN We developed a new class of recombinant antibodies called biobodies (Bb) and compared them to mAb for use in serodiagnosis. Bbs were secreted biotinylated in vivo by diploid yeast and used as affinity reagents after Ni purification. Bead-based assays for HE4 and mesothelin were developed using Bbs in combination with pAbs (Bb/pAb assays). To assess precision, reproducibility studies were done using four runs of 16 replicates at six analyte levels for each marker. Pearson correlations and receiver-operator characteristic analyses were done in 214 patient serum samples to directly compare the Bb/pAb assays to mAb assays. Diagnostic performance of the Bb/pAb assay was further assessed in an expanded set of 336 ovarian cancer cases and controls. RESULTS On average across analyte levels, Bb/pAb assays yielded within-run and between-run coefficients of variations of 11.7 and 23.8, respectively, for HE4 and 14.0 and 14.5, respectively, for mesothelin. In the subset (n = 214), Pearson correlations of 0.95 for HE4 and 0.92 for mesothelin were observed between mAb and Bb/pAb assays. The area under the curves for the mAb and Bb/pAb assays were not significantly different for HE4 (0.88 and 0.84, respectively; P = 0.20) or mesothelin (0.74 and 0.72, respectively; P = 0.38). CONCLUSION Yeast-secreted Bbs can be used reliably in cost-effective yet highly sensitive bead-based assays for use in large validation studies.
Collapse
Affiliation(s)
- Nathalie Scholler
- School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 96104-6069, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Lin L, Nemeth E, Goodnough JB, Thapa DR, Gabayan V, Ganz T. Soluble hemojuvelin is released by proprotein convertase-mediated cleavage at a conserved polybasic RNRR site. Blood Cells Mol Dis 2007; 40:122-31. [PMID: 17869549 PMCID: PMC2211380 DOI: 10.1016/j.bcmd.2007.06.023] [Citation(s) in RCA: 82] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2007] [Revised: 06/21/2007] [Accepted: 06/23/2007] [Indexed: 01/27/2023]
Abstract
As the principal iron-regulatory hormone, hepcidin plays an important role in systemic iron homeostasis. The regulation of hepcidin expression by iron loading appears to be unexpectedly complex and has attracted much interest. The GPI-linked membrane protein hemojuvelin (GPI-hemojuvelin) is an essential upstream regulator of hepcidin expression. A soluble form of hemojuvelin (s-hemojuvelin) exists in blood and acts as antagonist of GPI-hemojuvelin to downregulate hepcidin expression. The release of s-hemojuvelin is negatively regulated by both transferrin-bound iron (holo-Tf) and non-transferrin-bound iron (FAC), indicating s-hemojuvelin could be one of the mediators of hepcidin regulation by iron. In this report, we investigate the proteinase involved in the release of s-hemojuvelin and show that s-hemojuvelin is released by a proprotein convertase through the cleavage at a conserved polybasic RNRR site.
Collapse
Affiliation(s)
- Lan Lin
- Department of Pathology, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA
| | | | | | | | | | | |
Collapse
|
12
|
Song K, Sun X, Wang J, Zhou S, Zeng H, Chen F. Role of glycosylphosphatidylinositol-specific phospholipase D in the homing of umbilical cord blood, mobilized peripheral blood and bone marrow-derived hematopoietic stem/progenitor cells. Leuk Res 2007; 31:1701-7. [PMID: 17467053 DOI: 10.1016/j.leukres.2007.03.023] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2006] [Revised: 12/13/2006] [Accepted: 03/17/2007] [Indexed: 11/16/2022]
Abstract
Recent studies suggested that glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD) correlated with tumor malignancy and prognosis of certain tumors. As hematopoietic stem/progenitor cells (HS/PC) homing was similar to tumor invasion and metastasis in some mechanisms, which arose our interests in whether GPI-PLD contribution to the homing of HS/PC. In this study, CD34(+) cells from umbilical cord blood (UCB), mobilized peripheral blood (MPB), and bone marrow (BM) were assayed for their differences in adhesion, migration, respectively. The expression of GPI-anchored proteins (CD48, CD90) on the cells were analyzed by flow cytometry. Semi-quantitive RT-PCR was used to detect GPI-PLD expression in the three different CD34(+) cells. The results showed that GPI-PLD had no effect on the adhesion of CD34(+) cells. While, spontaneous and SDF-1 induced migration of UCB and MPB, but not BM CD34(+) cells were decreased after 1,10-phenanthroline (an inhibitor of GPI-PLD) pretreatment. Furthermore, we found little difference in GPI-anchored adhesion molecules (CD48, CD90) expression between untreated and pretreated CD34(+) cells. GPI-PLD mRNA was low expressed in MPB and undetected in UCB and BM CD34(+) cells. Our results suggested that GPI-PLD probably had no contribution to HS/PC homing, which may due to its low or no expression in UCB, BM and MPB CD34(+) cells.
Collapse
Affiliation(s)
- Kui Song
- Department of Hematology, Xiang Ya Hospital, Central South University, ChangSha 410008, PR China
| | | | | | | | | | | |
Collapse
|
13
|
Song K, Sun X, Wang J, Chen F. How Glycosylphosphatidylinositol-phospholipase D acts in homing of hematopoietic stem/progenitor cells? Med Hypotheses 2007; 69:660-5. [PMID: 17368745 DOI: 10.1016/j.mehy.2006.12.046] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2006] [Accepted: 12/07/2006] [Indexed: 10/23/2022]
Abstract
Homing of hematopoietic stem/progenitor cells (HS/PC) to the bone marrow (BM) microenvironment is the first and essential step in HS/PC engraftment and initiation of the marrow reconstitution during clinical hematopoietic stem cell transplantation (HSCT). How to improve the homing efficiencies and make full use of HS/PC resources, especially umbilical cord blood (UCB), are of great importance in clinical practice. However, the cellular and molecular mechanisms that govern this process are poorly understood. Glycosylphosphatidylinositol-phospholipase D (GPI-PLD) is an enzyme which can regulate the expression of Glycosylphosphatidylinositol (GPI)-anchored proteins and modulate their correspondent functions by releasing GPI-anchored proteins from cell membrane. Recent studies suggested that the mechanisms of the malignancy and prognosis of certain tumors were correlated with GPI-PLD. HS/PC homing was similar to tumor invasion and metastasis in some process. Here we proposed the hypothesis that GPI-PLD might also has played a role in the homing of HS/PC by modulating the adhesion and migration of these cells. If GPI-PLD did participate in HS/PC homing, maybe the mechanisms of homing can herefrom be partly elucidated, which would benefit transplantation in clinical practice.
Collapse
Affiliation(s)
- Kui Song
- Department of Hematology, Xiang Ya Hospital, Central South University, ChangSha 410008, PR China
| | | | | | | |
Collapse
|
14
|
Naghibalhossaini F, Ebadi P. Evidence for CEA release from human colon cancer cells by an endogenous GPI-PLD enzyme. Cancer Lett 2006; 234:158-67. [PMID: 15893415 DOI: 10.1016/j.canlet.2005.03.028] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2005] [Revised: 03/18/2005] [Accepted: 03/20/2005] [Indexed: 12/16/2022]
Abstract
Elevated carcinoembryonic antigen (CEA) blood levels are found in a wide variety of epithelial neoplasms. The precise mechanism of the spontaneous CEA release from normal and cancer cells has not been established yet. In this study we investigated 'in vitro' the role of an endogenous glycosylphosphatidyl inositol phospholipase D (GPI-PLD) in spontaneous CEA release from human colon carcinoma cells. We detected GPI-PLD-specific transcript expression in four human colorectal tumor cell lines, LS180, HT29, HT29/219, and SW742 by RT-PCR. Furthermore, CEA release could be activated and inhibited by incubation of LS180 cells with suramin and 1,10-phenanthroline, compounds known to activate and inhibit GPI-PLD activity, respectively. The results suggest a mechanism for the involvement of an endogenous GPI-PLD in spontaneous CEA release from human colon cancer cells.
Collapse
Affiliation(s)
- Fakhraddin Naghibalhossaini
- Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, 71345 Zand Street, P.O. Box 1167 Shiraz, Iran. fakhraddin.naghibalhossaini@elf,mcgill.ca
| | | |
Collapse
|
15
|
Jian-Hua T, Xiao-Jie Z, Yi-Dan W, Wen-Kai L, Wang-Jiao H, Cheng-Hong W, Gui-Yuan L. Effect of glycosylphosphatidylinositol specific phospholipase D gene expression levels on complement mediated killing of leukemic cells in patients with chronic myeloid leukemia. Clin Chim Acta 2005; 359:115-24. [PMID: 15907827 DOI: 10.1016/j.cccn.2005.03.045] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2004] [Revised: 03/12/2005] [Accepted: 03/15/2005] [Indexed: 10/25/2022]
Abstract
BACKGROUND To explore the disparity in glycosylphosphatidylinositol phospholipase D (GPI-PLD) expression levels between mononuclear cells of chronic myeloid leukemia (CML) and healthy controls, and clarify the certain relation of GPI-PLD expression levels to complement mediated killing of leukemic cells. METHODS Competitive RT-PCR was used to detect quantitatively the GPI-PLD mRNA in mononuclear cells. GPI-anchored CD55 and CD59 were analyzed by flow cytometry and Western blotting. Complement-mediated lysis was assessed by staining method of trypan blue dye. RESULTS The GPI-PLD activities and their mRNA copies in CML patients were significantly lower than those in healthy adults. At the tenth day after treatment with bone marrow transplantation (BMT), the GPI-PLD activities and copies of GPI-PLD mRNA almost recovered to the expression levels of healthy subjects. The expression of both CD55 and CD59 in CML patients were significantly higher than those in healthy subjects. After treatment with insulin (10(-7) mol/l) plus glucose (16.7 mmol/l) for 48 h, the cellular GPI-PLD activity and mRNA levels in K562 cells derived from the leukemic cells of a CML patient all increased about 3-fold. Simultaneously, the GPI-anchored CD55 and CD59 on cell surfaces were released into the culturing medium, and the killing rate of complement-mediated K562 cell lysis increased almost 3 times. CONCLUSION The decreased GPI-PLD expression may reduce the release of GPI-anchored CD55 and CD59 in leukemia cells and finally decrease complement mediated killing of these cells in chronic phase of CML.
Collapse
Affiliation(s)
- Tang Jian-Hua
- Department of Biochemistry, Institute of Biological Science and Technology, Central South University, Xiangya Road 88, Mail box 54number, Changsha, Hunan 410078, PR China.
| | | | | | | | | | | | | |
Collapse
|
16
|
Gregory P, Kraemer E, Zürcher G, Gentinetta R, Rohrbach V, Brodbeck U, Andres AC, Ziemiecki A, Bütikofer P. GPI-specific phospholipase D (GPI-PLD) is expressed during mouse development and is localized to the extracellular matrix of the developing mouse skeleton. Bone 2005; 37:139-47. [PMID: 15946906 DOI: 10.1016/j.bone.2005.04.015] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/03/2004] [Revised: 03/21/2005] [Accepted: 04/05/2005] [Indexed: 11/20/2022]
Abstract
Glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD) is abundant in serum and has a well-characterized biochemistry; however, its physiological role is completely unknown. Previous investigations into GPI-PLD have focused on the adult animal or on in vitro systems and a putative role in development has been neither proposed nor investigated. We describe the first evidence of GPI-PLD expression during mouse embryonic ossification. GPI-PLD expression was detected predominantly at sites of skeletal development, increasing during the course of gestation. GPI-PLD was observed during both intramembraneous and endochondral ossification and localized predominantly to the extracellular matrix of chondrocytes and to primary trabeculae of the skeleton. In addition, the mouse chondrocyte cell line ATDC5 expressed GPI-PLD after experimental induction of differentiation. These results implicate GPI-PLD in the process of bone formation during mouse embryogenesis.
Collapse
Affiliation(s)
- Patrick Gregory
- Institute of Biochemistry and Molecular Biology, University of Bern, Bühlstrasse 28, 3012 Bern, Switzerland
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Zambonelli C, Roberts MF. Non-HKD Phospholipase D Enzymes: New Players in Phosphatidic Acid Signaling? ACTA ACUST UNITED AC 2005; 79:133-81. [PMID: 16096028 DOI: 10.1016/s0079-6603(04)79003-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Affiliation(s)
- Carlo Zambonelli
- Merkert Chemistry Center, Boston College, Chestnut Hill, Massachusetts 02467, USA
| | | |
Collapse
|
18
|
Mann KJ, Hepworth MR, Raikwar NS, Deeg MA, Sevlever D. Effect of glycosylphosphatidylinositol (GPI)-phospholipase D overexpression on GPI metabolism. Biochem J 2004; 378:641-8. [PMID: 14611645 PMCID: PMC1223959 DOI: 10.1042/bj20031326] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2003] [Accepted: 11/11/2003] [Indexed: 11/17/2022]
Abstract
GPI-PLD [glycosylphosphatidylinositol (GPI)-specific phospholipase D (PLD)] is a secreted mammalian enzyme that specifically cleaves GPI-anchored proteins. In addition, the enzyme has been shown to cleave GPI anchor intermediates in cell lysates. The biosynthesis of the GPI anchor is well characterized; however, the mechanisms by which the levels of GPI anchor intermediates are regulated are still unknown. To investigate whether GPI-PLD plays a role in this regulation, we isolated stable HeLa cells overexpressing the enzyme. GPI-PLD-HeLa (GPI-PLD-transfected HeLa) cells showed a 3-fold increase in intracellular GPI-PLD activity and drastically decreased the levels of GPI-anchored proteins when compared with untransfected HeLa controls. Intracellular cleavage of GPI-anchored proteins has been suggested to occur early in the secretory pathway and, in agreement with this proposal, GPI-PLD activity in GPI-PLD-HeLa cells was detected not only in the endoplasmic reticulum and Golgi apparatus, but also in the plasma membrane. The enzyme was also active in lipid rafts, membrane microdomains in which GPI-anchored proteins and GPI anchor intermediates are concentrated, indicating that intracellular GPI-PLD cleavage may also occur in this compartment. Pulse-chase paradigms revealed the turnover rate of the last intermediate of the GPI anchor pathway in GPI-PLD-HeLa cells to be accelerated compared with the controls. Furthermore, 1,10-phenanthroline, a GPI-PLD inhibitor, reversed this effect. Our studies demonstrated that GPI-PLD can cleave not only GPI-anchored proteins, but also GPI anchor intermediates intracellularly. This observation opens the possibility that GPI-PLD can influence the steady-state levels of GPI-anchored proteins by hydrolysing the anchor before and after its attachment to proteins.
Collapse
Affiliation(s)
- Karl J Mann
- Department of Neuroscience, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, USA
| | | | | | | | | |
Collapse
|
19
|
Kawada M, Mizuno M, Nasu J, Uesu T, Okazaki H, Okada H, Shimomura H, Yamamoto K, Tsuji T, Fujita T, Shiratori Y. Release of decay-accelerating factor into stools of patients with colorectal cancer by means of cleavage at the site of glycosylphosphatidylinositol anchor. ACTA ACUST UNITED AC 2003; 142:306-12. [PMID: 14647034 DOI: 10.1016/s0022-2143(03)00137-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The expression of decay-accelerating factor (DAF), a cell-membrane-complement regulator, is enhanced in colorectal cancer, and DAF is detected in the stools of patients with colorectal cancer. In this study, to elucidate mechanisms whereby DAF is released into the colonic lumen, we analyzed and compared the properties of DAF in stools and colorectal-cancer tissues. Stool specimens taken before surgery and tissue samples from surgically resected colorectal cancers were obtained from 21 patients. We analyzed DAF in stool and tissue specimens using immunoblotting, ultracentrifugation, and phase separation with Triton X-114. We analyzed the expression profile of DAF mRNA in cancer tissues using reverse transcription-polymerase chain reaction to determine whether DAF transcripts for a secretory form of DAF were present. With the use of immunoblotting, stool DAF was detected as a broad band with a molecular weight of around 70,000 kDa that migrated slightly more slowly than cancer-tissue DAF. About 90% of stool DAF was present as a soluble form that remained in the 100,000 g supernatant after ultracentrifugation. On phase separation with Triton X-114, the soluble stool DAF was partitioned mainly into the aqueous phase, indicating its hydrophilic nature and lack of the fatty-acid glycosylphosphatidylinositol anchor component. In colorectal cancer tissues, reverse transcription-polymerase chain reaction experiments revealed a nonspliced DAF messenger RNA that encodes a secretory form of DAF in just 2 of the 21 specimens examined. These data suggest that DAF is released from colorectal cancer cells by way of cleavage of membrane-bound DAF at the site of the glycosylphosphatidylinositol anchor.
Collapse
Affiliation(s)
- Mikihiro Kawada
- Department of Medicine and Medical Sciences, Okayama University Graduate School of Medicine and Dentistry, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|